Literature DB >> 6355310

Estimation of the protective level of human IgG antibody to the type-specific polysaccharide of group B Streptococcus type Ia.

M E Klegerman, K M Boyer, C K Papierniak, S P Gotoff.   

Abstract

Human IgG antibody to the type-specific polysaccharide antigen of group B Streptococcus type Ia in the sera of mice was measured by enzyme-linked immunosorbent assay, previously standardized by quantitative precipitation, 24 hr after passive immunization with human serum or affinity-chromatographed antibody. The concentrations of antibody needed to protect mice against 90% lethal dose challenge varied with the bacterial inoculum and ranged from 0.25 to 1 microgram/ml using five strains of group B Streptococcus type Ia. Affinity-chromatographed antibody gave results comparable to serum, indicating the specificity of the antibody and the absence of other humoral factors in protection with this serum. Sera from 11 infected infants and their mothers had concentrations of antibody of less than or equal to 0.17 micrograms/ml, below the protective level delineated in the experimental model. Twelve percent of 50 adult women and 36% of 25 women colonized with group B Streptococcus type Ia had antibody levels of greater than or equal to 1 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355310     DOI: 10.1093/infdis/148.4.648

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

3.  Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib.

Authors:  K M Boyer; L S Kendall; C K Papierniak; M E Klegerman; S P Gotoff
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

4.  Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.

Authors:  Pia S Pannaraj; Morven S Edwards; Kristen T Ewing; Amanda L Lewis; Marcia A Rench; Carol J Baker
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

Review 5.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

Review 6.  Vaccines for Perinatal and Congenital Infections-How Close Are We?

Authors:  Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar
Journal:  Front Pediatr       Date:  2020-12-15       Impact factor: 3.418

7.  Status of group B streptococcal vaccine development.

Authors:  Shun Mei Lin; Yong Zhi; Ki Bum Ahn; Sangyong Lim; Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2018-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.